The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Fibroblast growth factor 21 protects the heart from oxidative stress
Abstract
AIMS: Oxidative stress mediated by reactive oxygen species (ROS) plays a striking role in the pathogenesis of heart failure, and antioxidants have been shown to attenuate cardiac remodelling in experimental models of cardiac damage. We recently showed that fibroblast growth factor 21 (Fgf21) is produced by the heart and exerts protective effects, preventing cardiac hypertrophy development. The aim of the study was to determine the effects of Fgf21 during oxidative stress signalling in the heart. METHODS AND RESULTS: Fgf21 treatment in cardiomyocytes in culture induced the expression of genes encoding proteins involved in antioxidative pathways, including mitochondrial uncoupling proteins (Ucp2 and Ucp3) and superoxide dismutase-2 (Sod2) and reduced ROS production. In keeping with this, expression of antioxidant genes in response to lipopolysaccharide (LPS)-induced stimulation of pro-inflammatory pathways or isoproterenol-induced cardiac hypertrophy in the heart was reduced in Fgf21-null mice. Moreover, we found that Fgf21 is expressed in and released by cardiomyocytes in response to LPS, and its expression is under the control of the Sirt1 (sirtuin-1) pathway. This Fgf21 released by cardiomyocytes acts in an autocrine manner to protect cells against oxidative stress. Finally, failing human hearts showed up-regulation of Fgf21, Ucp3, and Sod2, confirming the association between Fgf21 induction and the control of cardiac oxidative stress pathways. CONCLUSION: Our data indicate that Fgf21 regulates genes involved in antioxidant pathways in an autocrine manner, thus preventing ROS production in cardiac cells. Therefore, Fgf21 acts as an antioxidant factor in the heart, preventing induction of pro-oxidative pathways by inflammatory or hypertrophic conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Inagaki, T., Dutchak, P., Zhao, G., Ding, X., Gautron, L., Parameswara, V., Li, Y., Goetz, R., Mohammadi, M., Esser, V., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.003 · Cited by 1,504
Oxygen, oxidative stress, hypoxia, and heart failure
Giordano, F. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524408 · Cited by 1,496
Badman, M. K., Pissios, P., Kennedy, A. R., Koukos, G., Flier, J. S., & Maratos-Flier, E. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.05.002 · Cited by 1,495
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice
Cheng, H.-L., Mostoslavsky, R., Saito, S., Manis, J. P., Gu, Y., Patel, P., Bronson, R., Appella, E., Alt, F. W., & Chua, K. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934713100 · Cited by 1,095 · cited 1×
“Alt.(22) Fgf21-null mice (B6N;129S5-Fgf21/Mmcd) were obtained from the Mutant Mouse Regional Resource Center, an NCRR-NIH funded strain repository; these mice were donated to the MMRRC by Genentech, Inc.”
MethodMitochondrial superoxide: production, biological effects, and activation of uncoupling proteins
Brand, M. D., Affourtit, C., Esteves, T. C., Green, K., Lambert, A. J., Miwa, S., Pakay, J. L., & Parker, N. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.05.034 · Cited by 1,032
Kurosu, H., Choi, M., Ogawa, Y., Dickson, A. S., Goetz, R., Eliseenkova, A. V., Mohammadi, M., Rosenblatt, K. P., Kliewer, S. A., & Kuro-o, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704165200 · Cited by 748
Thermogenic Activation Induces FGF21 Expression and Release in Brown Adipose Tissue
Hondares, E., Iglesias, R., Giralt, A., Gonzalez, F. J., Giralt, M., Mampel, T., & Villarroya, F. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.215889 · Cited by 623
Self-citationSmall molecule SIRT1 activators for the treatment of aging and age-related diseases
Hubbard, B. P., & Sinclair, D. A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.12.004 · Cited by 569
Silent Information Regulator 1 Protects the Heart From Ischemia/Reperfusion
Hsu, C.-P., Zhai, P., Yamamoto, T., Maejima, Y., Matsushima, S., Hariharan, N., Shao, D., Takagi, H., Oka, S., & Sadoshima, J. (2010) · Circulation · doi:10.1161/circulationaha.110.958033 · Cited by 560
Gälman, C., Lundåsen, T., Kharitonenkov, A., Bina, H. A., Eriksson, M., Hafström, I., Dahlin, M., Åmark, P., Angelin, B., & Rudling, M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.014 · Cited by 512
FGF21 is an Akt‐regulated myokine
Izumiya, Y., Bina, H. A., Ouchi, N., Akasaki, Y., Kharitonenkov, A., & Walsh, K. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.021 · Cited by 415
Hondares, E., Rosell, M., Gonzalez, F. J., Giralt, M., Iglesias, R., & Villarroya, F. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.02.001 · Cited by 377 · cited 1×
“6 Endocrine actions of Fgf21 include the promotion of glucose uptake by white adipocytes through induction of the glucose transporter Glut1(7) and activation of brown fat thermogenic activity.(8) Action of Fgf21 on target cells requires FGF receptors (mainly Fgfr1 and Fgfr4 in adipose tissue and liver, respectively) a…”
BackgroundSelf-citationMitochondrial oxidative stress and dysfunction in myocardial remodelling
Tsutsui, H., Kinugawa, S., & Matsushima, S. (2008) · Cardiovascular Research · doi:10.1093/cvr/cvn280 · Cited by 377
Fibroblast growth factor 21 protects against cardiac hypertrophy in mice
Planavila, A., Redondo, I., Hondares, E., Vinciguerra, M., Munts, C., Iglesias, R., Gabrielli, L. A., Sitges, M., Giralt, M., van Bilsen, M., et al. (2013) · Nature Communications · doi:10.1038/ncomms3019 · Cited by 371
Self-citationFGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho
Kharitonenkov, A., Dunbar, J. D., Bina, H. A., Bright, S., Moyers, J. S., Zhang, C., Ding, L., Micanovic, R., Mehrbod, S. F., Knierman, M. D., et al. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21357 · Cited by 328
Planavila, A., Iglesias, R., Giralt, M., & Villarroya, F. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvq376 · Cited by 317
Self-citationMuise, E. S., Azzolina, B., Kuo, D. W., El-Sherbeini, M., Tan, Y., Yuan, X., Mu, J., Thompson, J. R., Berger, J. P., & Wong, K. K. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.044826 · Cited by 294
Lipopolysaccharide induces oxidative cardiac mitochondrial damage and biogenesis
SULIMAN, H., WELTYWOLF, K., CARRAWAY, M., TATRO, L., & PIANTADOSI, C. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.07.005 · Cited by 269
Amat, R., Planavila, A., Chen, S. L., Iglesias, R., Giralt, M., & Villarroya, F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.022749 · Cited by 218
Self-citationEndocrine Protection of Ischemic Myocardium by FGF21 from the Liver and Adipose Tissue
Liu, S. Q., Roberts, D., Kharitonenkov, A., Zhang, B., Hanson, S. M., Li, Y. C., Zhang, L.-Q., & Wu, Y. H. (2013) · Scientific Reports · doi:10.1038/srep02767 · Cited by 180
Cantu, D., Schaack, J. B., & Patel, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007095 · Cited by 151
Okumura, S., Vatner, D. E., Kurotani, R., Bai, Y., Gao, S., Yuan, Z., Iwatsubo, K., Ulucan, C., Kawabe, J.-I., Ghosh, K., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.698662 · Cited by 133
Schilling, J. D., Lai, L., Sambandam, N., Dey, C. E., Leone, T. C., & Kelly, D. P. (2011) · Circulation Heart Failure · doi:10.1161/circheartfailure.110.959833 · Cited by 132
mIGF‐1/JNK1/SirT1 signaling confers protection against oxidative stress in the heart
Vinciguerra, M., Santini, M. P., Martínez, C., Pazienza, V., Claycomb, W. C., Giuliani, A., & Rosenthal, N. A. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00766.x · Cited by 130
Planavila, A., Laguna, J. C., & Vázquez‐Carrera, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414220200 · Cited by 129
Self-citationVinciguerra, M., Santini, M. P., Claycomb, W. C., Ladurner, A. G., & Rosenthal, N. A. (2009) · Aging · doi:10.18632/aging.100107 · Cited by 116
Lai, L., Yan, L., Gao, S., Hu, C., Ge, H., Davidow, A. L., Park, M., Bravo, C., Iwatsubo, K., Ishikawa, Y., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.001212 · Cited by 115
The breathing heart — Mitochondrial respiratory chain dysfunction in cardiac disease
Schwarz, K., Siddiqi, N., Singh, S., Neil, C., Dawson, D. K., & Frenneaux, M. P. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.12.014 · Cited by 108
SIRT1 Is Involved in Glucocorticoid-mediated Control of Uncoupling Protein-3 Gene Transcription
Amat, R., Solanes, G., Giralt, M., & Villarroya, F. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707114200 · Cited by 90
Self-citationRole of uncoupling protein 3 in ischemia-reperfusion injury, arrhythmias, and preconditioning
Özcan, C., Palmeri, M., Horváth, T. L., Russell, K. S., & Russell, R. R. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00592.2012 · Cited by 87
Heusch, P., Canton, M., Aker, S., van de Sand, A., Konietzka, I., Rassaf, T., Menazza, S., Brodde, O. E., Lisa, F. D., Heusch, G., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00793.x · Cited by 72
SirT1 in muscle physiology and disease: lessons from mouse models
Vinciguerra, M., Fulco, M., Ladurner, A. G., Sartorelli, V., & Rosenthal, N. A. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.004655 · Cited by 70
Perrino, C., Schiattarella, G. G., Sannino, A., Pironti, G., Petretta, M. P., Cannavò, A., Gargiulo, G., Ilardi, F., Magliulo, F., Franzone, A., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000086 · Cited by 57
Cardiac Function and Circulating Cytokines Following Endotoxin Exposure in Neonatal Mice
Mukherjee, R. D., McQuinn, T. C., Dugan, M. A., Saul, J. P., & Spinale, F. G. (2010) · Pediatric Research · doi:10.1203/pdr.0b013e3181efbe10 · Cited by 20
Shang, F., Zhao, L., Zheng, Q., Wang, J., Xu, Z., Liang, W., Liu, H., Liu, S., & Zhang, L. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.134 · Cited by 20
Cited by
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
Oxidative Stress, Inflammation, and Vascular Aging in Hypertension
Guzik, T. J., & Touyz, R. M. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.07802 · Cited by 766
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Geng, L., Lam, K. S. L., & Xu, A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0386-0 · Cited by 607
The role of infiltrating immune cells in dysfunctional adipose tissue
Guzik, T. J., Skiba, D. S., Touyz, R. M., & Harrison, D. G. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx108 · Cited by 445
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Degirolamo, C., Sabbà, C., & Moschetta, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.9 · Cited by 424
Metadata
- Authors
- Planavila, A., Redondo-Angulo, I., Ribas, F., Garrabou, G., Casademont, J., Giralt, M., & Villarroya, F.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-12-23
- Volume
- 106
- Issue
- 1
- Pages
- 19-31
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W2136624264
- Cited by
- 265
- References
- 36
- FWCI
- 8.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.